| |
Decentralized clinical trials (DCTs) are redefining clinical research beyond the confines of traditional clinical trial sites. This recent shift presents immense promise for pediatric rare disease research – offering hope to patients and their families as they navigate the uncertainty of their diagnoses. Read our checklist to explore expert insights for the implementation of decentralized clinical trials in pediatric rare diseases. +(002)+120w.png)
|
|
Today’s Big NewsApr 19, 2024 |
| By Annalee Armstrong Vir Biotechnology conducted a world-wide search to find the perfect CEO. In the end, the board picked Bayer’s Marianne De Backer because of her three decades of experience in the pharmaceutical industry and her “deep and thorough understanding of the evolving healthcare landscape.” |
|
|
|
By James Waldron Barinthus Biotherapeutics has hit the primary endpoint of a phase 1b/2 trial by showing its treatment for high risk human papillomavirus-associated cervical cancer is safe. But the failure to prove the therapy actually works has left the biotech mulling how to take the candidate further. |
By Max Bayer Sanofi's global restructuring is becoming clearer, with employees in Belgium the latest to be impacted. The French pharma expanded its footprint in Ghent after acquiring Ablynx in 2018. |
By Max Bayer,Gabrielle Masson AI-infused drug developer Recursion has hired Najat Khan, Ph.D., as chief commercial officer and head of R&D. She joins from Johnson & Johnson where she was chief data science officer and head of strategy and portfolio within the pharma R&D team. |
|
Tuesday, April 23, 2024 | 2:00pm ET | 11:00am PT If you are embarking on the exciting journey of moving labs, this webinar is for you! Join us on April 23rd to learn from real-life stories the critical steps to a successful move and the common budget-draining mistakes to avoid. Register today! 
|
|
By Gabrielle Masson,Annalee Armstrong,Max Bayer Welcome to Fierce Biotech's Fundraising Tracker, 2024's version. |
By Helen Floersh Merck KGaA subsidiary MilliporeSigma has developed a first-of-its-kind “all-in-one” CHO genetic stability assay. The company claims that the platform, called Aptegra, cuts biosafety testing time for clients by two-thirds and subsequently speeds up the commercialization process. |
By Annalee Armstrong A thinner, leaner biotech forest arrived at the American Association for Cancer Research conference in San Diego ready to showcase the budding data that has sprouted as a result of difficult decisions made during the sector’s so-called “nuclear winter.” |
By Eric Sagonowsky During a busy period of overhaul at Sanofi, the company is restructuring its U.S. vaccine commercial group. A spokesperson said the company would offer affected employees a chance to apply for new roles, plus "outplacement services." |
By Emma Beavins House lawmakers revived discussions of a national data privacy law at an Energy & Commerce hearing Wednesday. Here are the key takeaways. |
By Angus Liu Amgen CEO Robert Bradway scored a 5.8% increase in overall compensation last year mostly thanks to the company's acquisition of Horizon Therapeutics. |
By Andrea Park As industries around the globe wrestle with where and how often artificial intelligence should be implemented in their workflows, biopharma, for one, is proceeding with caution. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," we are joined by Annalee Armstrong, Senior Editor at Fierce Biotech, and Ben Adams, Senior Editor of Fierce Pharma Marketing, to discuss Fierce's take on March Madness. |
|
|---|
|
|
|
Tuesday, April 30, 2024 | 2pm ET / 11am PT Liquid biopsies have shown tremendous progress for the early detection of cancer and for treatment monitoring, but still have limitations. The inclusion of protein glycosylation can help. Join usto learn more about the latest solutions for leveraging AI and machine learning to accelerate data processing, overcome current barriers, and provide crucial information. Register now. 
|
|
Whitepaper Antibody biomarkers are redefining precision medicine, from diagnosing diseases earlier to stratifying patients – download your FREE white paper today! Sponsored by: Sengenics Corporation LLC |
Whitepaper The use of prefilled syringes to administer biotherapeutics is beginning to gain traction because they offer a range of stability, efficacy, and patient safety benefits. Download this white paper to learn how Lonza has developed a novel workflow to ensure confidence regarding functionality in PFS and autoinjectors. Presented by Lonza |
eBook Unlock the future of monoclonal antibody (mAb) manufacturing with a complete guide to enhancing productivity and quality for exceptional outcomes. Sponsored by: Thermo Fisher Scientific |
Whitepaper This paper assesses the current state of the oncology market, reviewing key expectations for 2024. It addresses CAR-T therapies, KRAS, radiopharmaceuticals, & targeted protein degradation. Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper Choosing the right contract lab can help drug developers accelerate their timelines and generate cost-efficiencies. For insights into what to look for when selecting a GMP/CMC lab partner read this white paper which delves into a range of factors that can support your needs in both the short-term and in planning for the future. Sponsored by: PPD®️ Laboratory Services |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
